Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6745723 | 0.83 | MAOB (0.46) | MAOBTAAR1SLC6A2CYP1A2CYP2C19 | |
| SCHEMBL315315 | 0.79 | MAOB (0.52) | MAOBTAAR1SLC6A2CYP1A2CYP2D6 | |
| SCHEMBL10409227 | 0.74 | MAOB (0.41) | MAOBTAAR1SLC6A2CYP1A2CYP2C19 | |
| SCHEMBL9260781 | 0.71 | HRH1 (0.40) | SLC6A2MAPK1LMNA | |
| SCHEMBL23524584 | 0.70 | MAOB (0.52) | MAOBTAAR1SLC6A2LMNATP53 | |
| SCHEMBL144711 | 0.70 | MAOB (0.52) | MAOBTAAR1SLC6A2TP53CA1 | |
| SCHEMBL4450792 | 0.67 | MAPK1 (0.44) | TAAR1CYP2C19CYP3A4MAPK1HIF1A | |
| SCHEMBL28563681 | 0.67 | ALDH1A1 (0.46) | TAAR1CYP1A2CYP2C19CYP3A4MAPK1 | |
| SCHEMBL2121346 | 0.67 | ESR1 (0.44) | TAAR1CYP2C19CYP3A4MAPK1HIF1A | |
| SCHEMBL8635078 | 0.67 | TAAR1 (0.52) | TAAR1SLC6A2CYP1A2CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011588-A1 | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid | BAUSCH & LOMB PHARMA HOLDINGS CORP. | 2015-01-08 | — | — | US | disclosed |
| EP-1796641-A1 | A NOVEL FORMULATION, OMEPRAZOLE ANTACID COMPLEX-IMMEDIATE RELEASE FOR RAPID AND SUSTAINED SUPPRESSION OF GASTRIC ACID | Santarus, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
| WO-2006031256-A1 | A NOVEL FORMULATION, OMEPRAZOLE ANTACID COMPLEX-IMMEDIATE RELEASE FOR RAPID AND SUSTAINED SUPPRESSION OF GASTRIC ACID | SANTARUS, INC (US) | 2006-03-23 | — | — | WO | disclosed |
| EP-1603537-A2 | A NOVEL FORMULATION, OMEPRAZOLE ANTACID COMPLEX-IMMEDIATE RELEASE FOR RAPID AND SUSTAINED SUPRESSION OF GASTRIC ACID | SANTARUS, INC. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050220870-A1 | administering mixtures of proton pump inhibitors and buffers, used for prophylaxis of gastrointestinal disorders | BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC) (HU) | 2005-10-06 | — | — | US | disclosed |
| US-20040248942-A1 | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2004-12-09 | — | — | US | disclosed |
| WO-2004073654-A2 | A NOVEL FORMULATION, OMEPRAZOLE ANTACID COMPLEX-IMMEDIATE RELEASE FOR RAPID AND SUSTAINED SUPRESSION OF GASTRIC ACID | SANTARUS, INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040127539-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | disclosed |
| US-20030087942-A1 | Method for the treatment and prevention of cachexia | WASHINGTON UNIVERSITY | 2003-05-08 | — | — | US | disclosed |
| WO-2003020268-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF CACHEXIA | WASHINGTON UNIVERSITY (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020128232-A1 | Heterocyclic angiogenesis inhibitors | STARPHARMA LIMITED (AU) | 2002-09-12 | — | — | US | disclosed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | disclosed |
| WO-2002030886-A2 | HETEROCYCLIC ANGIOGENESIS INHIBITORS | MATTHEWS BARRY R (AU) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050220870-A1 | administering mixtures of proton pump inhibitors and buffers, used for prophylaxis of gastrointestinal disorders | PGA5, SI, HRH2 | MAOB 552/4885TAAR1 2892/4885SLC6A2 512/4885 |
| US-20150011588-A1 | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid | PGA5, GIPR, ATP6AP1 | MAOB 905/4885TAAR1 2290/4885SLC6A2 248/4885 |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | MAOB 2195/4885TAAR1 4084/4885SLC6A2 2532/4885 |
| US-20020128232-A1 | Heterocyclic angiogenesis inhibitors | KDR, CBR3, OGFR | MAOB 599/4885TAAR1 453/4885SLC6A2 2494/4885 |
| US-20030087942-A1 | Method for the treatment and prevention of cachexia | TNF, PTGES2, PTGS2 | MAOB 2321/4885TAAR1 2522/4885SLC6A2 4265/4885 |
| US-20040248942-A1 | Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid | PGA5, GIPR, ATP6AP1 | MAOB 905/4885TAAR1 2290/4885SLC6A2 248/4885 |
| US-20040127539-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | MAOB 2195/4885TAAR1 4084/4885SLC6A2 2532/4885 |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | MAOB 3473/4885TAAR1 3873/4885SLC6A2 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.